SAB Biotherapeutics
SABS • NASDAQ • Stock Fundamentals
SAB Biotherapeutics is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Samuel J. Reich, with a market cap of $298.2M.
Market Cap$298.2M
Employees57.0
CEOSamuel J. Reich
CountryUnited States of America
Healthcare
Biotechnology
Most Recent EarningsMay 12, 2026 · 16 days agoQ1 2026
View reportNext EarningsAug 6, 2026 · in 2 monthsQ2 2026
Financials
Based on Q1 2026 filing
SAB Biotherapeutics FAQ
Common questions about SAB Biotherapeutics
SAB Biotherapeutics (SABS) has a market capitalization of $298.2M and trades on NASDAQ.
SAB Biotherapeutics has approximately 57 employees.